Camurus AB (publ) (0RD1.L)
LSE - LSE Delayed price. Currency in SEK
Add to watchlist
At close: 04:13PM BST
| Previous close | 566.50 |
| Open | 565.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 559.00 - 568.50 |
| 52-week range | 197.70 - 596.00 |
| Volume | |
| Avg. volume | 24,529 |
| Market cap | 261.012M |
| Beta (5Y monthly) | 0.84 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.27 |
| Earnings date | 16 July 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireCamurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegaly
Camurus (NASDAQ STO: CAMX) today announced topline, interim data from an open-label, long-term safety and extension trial, ACROINNOVA 2, assessing CAM2029, octreotide subcutaneous (SC) depot, in 135 adult patients with acromegaly. These include both new patients and roll-over patients from the previous randomized controlled trial, ACROINNOVA 1, where they received treatment with CAM2029 or placebo ('treatment naïve' patients). The Phase 3 data show a favorable safety profile and robust long-term
© 2024 Yahoo. All rights reserved.